Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Wave Life SciencesWVE | Open-market buy | 03/26–03/30 | 03/30 | 8,772,496 sh4 trades | $6.23avg. | $54,624,377.99 | +48.2% | |
Director | Wave Life SciencesWVE | Open-market buy | 03/26–03/30 | 03/30 | 8,772,496 sh4 trades | $6.23avg. | $54,624,377.99 | +48.2% |
Wave Life SciencesWVE | Open-market buy | 03/26–03/30 | 03/30 | 8,772,496 sh4 trades | $6.23avg. | $54,624,377.99 | +48.2% | |
Wave Life SciencesWVE | Open-market buy | 03/26–03/30 | 03/30 | 8,772,496 sh4 trades | $6.23avg. | $54,624,377.99 | +48.2% | |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 02/26 | 02/27 | 33,194 sh2 trades | $15.05avg. | $499,521 | −34.9% | |
Chandra VargeeseSEE REMARKS | Wave Life SciencesWVE | Open-market sale | 02/09 | 02/11 | 3,228 sh | $13.45 | $43,416.6 | −0.8% |
Chris FrancisSEE REMARKS | Wave Life SciencesWVE | Open-market sale | 02/09 | 02/11 | 1,883 sh | $13.45 | $25,326.35 | −3.0% |
Paul BolnoPresident and CEO | Wave Life SciencesWVE | Open-market sale | 02/09 | 02/11 | 10,480 sh | $13.45 | $140,956 | −3.7% |
Kyle MoranCFO | Wave Life SciencesWVE | Open-market sale | 02/09 | 02/11 | 3,588 sh | $13.45 | $48,258.6 | −2.6% |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 01/02 | 01/06 | 9,375 sh2 trades | $16.03avg. | $150,260.1 | −27.3% | |
GSK10% Owner | Wave Life SciencesWVE | Open-market buy | 25/12/11 | 25/12/15 | 1,470,000 sh | $19.00 | $27,930,000 | +8.8% |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08–25/12/09 | 25/12/10 | 260,036 sh6 trades | $15.78avg. | $4,104,229 | −74.2% | |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 16,115 sh2 trades | $13.49avg. | $217,330.05 | −35.9% | |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 93,445 sh4 trades | $14.65avg. | $1,369,323.75 | −88.0% | |
Rawcliffe AdrianDirector | Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 42,000 sh | $15.00 | $630,000 | −76.8% |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 20,000 sh2 trades | $13.47avg. | $269,460.8 | −6.8% | |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 14,000 sh2 trades | $13.50avg. | $189,000 | −23.8% | |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 441,031 sh9 trades | $14.58avg. | $6,428,126.3 | −94.6% | |
Wave Life SciencesWVE | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 134,218 sh8 trades | $13.58avg. | $1,823,158.5 | −84.1% | |
RA Capital Healthcare FundDirector | Wave Life SciencesWVE | Open-market buy | 25/11/13 | 25/11/14 | 1,000 sh | $6.69 | $6,690 | +0.0% |
